Edwards Lifesciences Q3 Sales Rise 10.5% to $1.72 Billion; Raises 2026 Outlook
Edwards Lifesciences beat its growth plan across structural heart and raised full-year sales and earnings guidance after a strong third quarter.
Irvine, California-based Edwards reported sales of $1.72 billion for the quarter ended Sept. 30, 2026, up 10.5%, or 11.2% on a constant-currency basis, according to its earnings release filed with an 8-K Wednesday. GAAP EPS was $0.53. Adjusted EPS was $0.80, up 19% from a year earlier.
Transcatheter aortic valve replacement sales were $1.24 billion, up 8.0%, or 8.8% constant currency. Transcatheter mitral and tricuspid therapies sales jumped 44.0% to $207 million, or 45.6% constant currency. CEO Bernard Zovighian said broad-based regional performance supported the raise to the full-year outlook.
Guidance and pipeline
Edwards raised 2026 total company sales growth guidance to an estimated 11.5% from 10% to 11%, the company said. TAVR sales growth guidance moved to 9.0% to 9.5% from 8% to 9%. TMTT sales guidance rose to $780 million to $790 million from $760 million to $780 million. Adjusted EPS guidance increased to $2.97 to $3.05 from $2.95 to $3.05, implying 18% growth at the midpoint.
The company also highlighted clinical and regulatory milestones, including PROGRESS trial data in moderate aortic stenosis, a final TAVR national coverage determination step, U.S. approvals for PASCAL Precision (tricuspid) and PASCAL Ace, European approval of SAPIEN M3 RESILIA, and U.S. approval of AUTUS for pediatric congenital heart disease.
TAVR average selling prices were stable globally, management said, so the 8% sales increase was volume-led rather than price-led. Similar growth rates in the U.S. and outside the U.S. reduce the usual geographic-mix worry that has shadowed prior TAVR quarters.
Why it matters
EW remains the core structural-heart compounder for many retail growth portfolios. Mid-teens company growth, high-single-digit TAVR and 44% TMTT growth—with a higher guide—keep the thesis intact even as TAVR matures. The pipeline and coverage headlines are the longer-duration upside that usually matters more than any single quarter’s EPS.
By the numbers
- Q3 sales: $1.72 billion, up 10.5% (11.2% CC)
- TAVR sales: $1.24 billion, up 8.0%
- TMTT sales: $207 million, up 44.0%
- GAAP EPS: $0.53
- Adjusted EPS: $0.80, up 19%
- 2026 adjusted EPS guide: $2.97 to $3.05
Sources
- Edwards Lifesciences Form 8-K with third-quarter 2026 results, filed Nov. 4, 2026 (accession 0001099800-26-000053)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.